|
|
Decoding the language of inflammation between central nervous system resident immune cells |
| 1 DP2 AI154435-01 |
CLARK, IAIN |
NIAID |
2021 |
|
|
Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity |
| 1 DP2 AI164306-01 |
WILSON, DAVID SCOTT |
NIAID |
2021 |
|
|
Investigating Complement Component 3a Signaling in Viral Neuroinflammatory Responses. |
| 1 F30 AI157165-01A1 |
KANMOGNE, MARLENE |
NIAID |
2021 |
|
|
Human antibody modification of enterovirus D68 infection |
| 1 K08 AI156125-01A1 |
VOGT, MATTHEW R |
NIAID |
2021 |
|
|
Design and development of HDAC11-specific chemical inhibitors for disease treatments |
| 1 R01 AI153110-01A1 |
SETO, EDWARD |
NIAID |
2021 |
|
|
Defining the Role of DNA Rereplication of Chromosome 21 in the Development and Pathophysiology of Down Syndrome |
| 1 R01 AI155918-01 |
BLACK, JOSHUA CRANSTON |
NIAID |
2021 |
|
|
ThGM Cells in CNS Autoimmunity |
| 1 R01 AI155974-01A1 |
ROSTAMI, AM |
NIAID |
2021 |
|
|
Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis |
| 1 R01 AI156186-01A1 |
CIOFANI, MARIA |
NIAID |
2021 |
|
|
Role of IL-7R in CNS autoimmunity |
| 1 R01 AI156384-01 |
ROSTAMI, AM |
NIAID |
2021 |
|
|
IL-37: a novel regulator of inflammation in CNS autoimmunity |
| 1 R01 AI160189-01 |
ROSTAMI, AM |
NIAID |
2021 |
